CAMP4 THERAPEUTICS CORPORATION (CAMP)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
4.45 USD
-0.05
(-1.111%) ⇩
(July 14, 2026, 4 p.m.
EDT)
After hours: 4.43 -0.02 (-0.020%) ⇩ (July 14, 2026, 5:34 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:19 a.m. EDT
The short-term outlook remains neutral despite a recent uptick in price, as the statistical forecasting model offers a weak bearish lean with very low confidence, failing to provide a clear directional edge for immediate trading. The long-term investment case is fundamentally compromised by severe financial distress; the company reports negative earnings, negative free cash flow, and negative operating margins, while the price-to-sales ratio of 57x suggests the market is pricing in significant future success that has not yet materialized. Furthermore, the price history is too short to establish a multi-year trend, preventing an assessment of sustained business quality or structural decline based on historical performance. There is no dividend income to offset these risks, making this a speculative biotech play rather than an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044723 |
| MSTL | 0.051947 |
| AutoARIMA | 0.057112 |
| AutoETS | 0.058147 |
| MSTL_73 | 0.122050 |
| MSTL_48_73 | 0.130529 |
| MSTL_48 | 0.149103 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.74 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.867 |
| Revenue per Share | 0.099 |
| Market Cap | 231,069,808 |
| Forward P/E | -5.72 |
| Website | https://www.camp4tx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.125 |
| Address1 | One Kendall Square |
| Address2 | 3rd Floor Building 1400 West |
| All Time High | 12.3 |
| All Time Low | 1.305 |
| Ask | 5.68 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 178,830 |
| Average Daily Volume3 Month | 171,995 |
| Average Volume | 171,995 |
| Average Volume10Days | 178,830 |
| Bid | 3.4 |
| Bid Size | 2 |
| Book Value | 0.595 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.45 |
| Current Ratio | 6.148 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.71 |
| Day Low | 4.43 |
| Debt To Equity | 6.867 |
| Display Name | Camp4 Therapeutics |
| Earnings Timestamp End | 1,755,028,800 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda | -50,294,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.664 |
| Enterprise To Revenue | 34.058 |
| Enterprise Value | 133,982,808 |
| Eps Current Year | -0.7932 |
| Eps Forward | -0.77858 |
| Eps Trailing Twelve Months | -2.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.2492 |
| Fifty Day Average Change | 0.20079994 |
| Fifty Day Average Change Percent | 0.04725594 |
| Fifty Two Week Change Percent | 212.5 |
| Fifty Two Week High | 7.75 |
| Fifty Two Week High Change | -3.3000002 |
| Fifty Two Week High Change Percent | -0.42580646 |
| Fifty Two Week Low | 1.32 |
| Fifty Two Week Low Change | 3.1299996 |
| Fifty Two Week Low Change Percent | 2.3712118 |
| Fifty Two Week Range | 1.32 - 7.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,728,653,400,000 |
| Float Shares | 27,468,229 |
| Forward Eps | -0.77858 |
| Forward P E | -5.7155333 |
| Free Cashflow | -13,805,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 48 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -34,282,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13068 |
| Held Percent Institutions | 0.86661005 |
| Implied Shares Outstanding | 51,925,800 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Market | us_market |
| Market Cap | 231,069,808 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_569025678 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -86,301,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 233,666,100 |
| Number Of Analyst Opinions | 6 |
| Open | 4.52 |
| Operating Cashflow | -26,248,000 |
| Operating Margins | -10.10124 |
| Payout Ratio | 0.0 |
| Phone | 617 651 8867 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.4494378 |
| Post Market Price | 4.43 |
| Post Market Time | 1,784,064,867 |
| Previous Close | 4.5 |
| Price Eps Current Year | -5.610186 |
| Price Hint | 4 |
| Price To Book | 7.478991 |
| Price To Sales Trailing12 Months | 58.736607 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.968 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -0.05000019 |
| Regular Market Change Percent | -1.1111153 |
| Regular Market Day High | 4.71 |
| Regular Market Day Low | 4.43 |
| Regular Market Day Range | 4.43 - 4.71 |
| Regular Market Open | 4.52 |
| Regular Market Previous Close | 4.5 |
| Regular Market Price | 4.45 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 164,447 |
| Return On Assets | -0.38661 |
| Return On Equity | -2.0928102 |
| Revenue Growth | 0.508 |
| Revenue Per Share | 0.099 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 51,925,800 |
| Shares Percent Shares Out | 0.0253 |
| Shares Short | 1,311,363 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 340,940 |
| Short Name | CAMP4 THERAPEUTICS CORPORATION |
| Short Percent Of Float | 0.0373 |
| Short Ratio | 4.21 |
| Source Interval | 15 |
| State | MA |
| Symbol | CAMP |
| Target High Price | 12.0 |
| Target Low Price | 6.5 |
| Target Mean Price | 8.58333 |
| Target Median Price | 8.5 |
| Total Cash | 99,209,000 |
| Total Cash Per Share | 1.911 |
| Total Debt | 2,122,000 |
| Total Revenue | 3,934,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.393725 |
| Two Hundred Day Average Change | 0.05627489 |
| Two Hundred Day Average Change Percent | 0.012808014 |
| Type Disp | Equity |
| Volume | 164,447 |
| Website | https://www.camp4tx.com |
| Zip | 2,139 |